What impact could Medicaid policy changes have on cell therapy reimbursement?

Proposed Medicaid policy changes, including outcome-based and annuity payment models, aim to enhance access to costly cell and gene therapies (CGTs) while addressing state budget constraints^[6]. These changes could alleviate immediate financial burdens by spreading costs over time and tying payments to patient outcomes^[6].

Current reimbursement models often leave states with stringent utilization controls, limiting access to innovative treatments, particularly for high-cost therapies^[5]. If successfully implemented, these policy adjustments could not only reduce hospital budget impacts but also enhance patient access to essential therapies that address severe health conditions^[3].